High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
暂无分享,去创建一个
Diane D. Liu | G. Hortobagyi | V. Valero | Yu Shen | N. Ueno | M. Chávez-MacGregor | Jimin Wu | T. Fujii | T. Fouad | R. Alvarez | H. Masuda | T. Kogawa